Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy

Daiki Ueno(University of California, Los Angeles), Brian Shuch(UCLA Medical Center)
Oncotarget
September 14, 2022
Cited by 15


Related Papers